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BACKGROUND: Delays in the diagnosis of children with fragile X syndrome (FXS) suggest the 
possibility of newborn screening as a way to identify children earlier. However, FXS does not 
have a proven treatment that must be provided early, and ethical concerns have been raised 
about the detection of infants who are carriers. This article summarizes major findings from 
a multisite, prospective, longitudinal pilot screening study.
METHODS: Investigators in North Carolina, California, and Illinois collaborated on a study 
in which voluntary screening for FXS was offered to parents in 3 birthing hospitals. 
FXS newborn screening was offered to >28 000 families to assess public acceptance and 
determine whether identification of babies resulted in any measurable harms or adverse 
events. Secondary goals were to determine the prevalence of FMR1 carrier gene expansions, 
study the consent process, and describe early development and behavior of identified 
children.
RESULTS: A number of publications have resulted from the project. This article summarizes 10 
“lessons learned” about the consent process, reasons for accepting and declining screening, 
development and evaluation of a decision aid, prevalence of carriers, father participation in 
consent, family follow-up, and maternal reactions to screening.
CONCLUSIONS: The project documented public acceptance of screening as well as the challenges 
inherent in obtaining consent in the hospital shortly after birth. Collectively, the study 
provides answers to a number of questions that now set the stage for a next generation of 
research to determine the benefits of earlier identification for children and families.
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Despite the appearance of symptoms 
during the first year of life and early 
concerns of parents, timely diagnosis 
of children with fragile X syndrome 
(FXS) remains a persistent challenge 
that has proved difficult to remediate. 
The average age of diagnosis for 
boys with the full mutation (>200 
CGG repeats in the FMR1 gene), who 
typically have moderate intellectual 
and developmental delays and a 
variety of associated conditions, 1 
is around 36 months, essentially 
unchanged despite a variety of 
awareness activities and professional 
guidelines. 2 – 4 For families, a late 
diagnosis can result in repeated 
physician visits, lack of early 
intervention services, and, for 
some, the birth of additional 
children with FXS before the first is 
diagnosed.
Parents of affected children strongly 
support earlier screening, 5 – 7 
and professionals from several 
disciplines have generally 
favorable opinions about earlier 
identification. 8 – 12 Whether newborn 
screening (NBS) is the answer has 
been debated, in part because no 
treatment has been shown to be 
effective in the earliest years, an 
essential requirement for state-
mandated NBS programs. 13– 15 
Beyond lack of data on treatment 
efficacy, NBS for FXS evokes a 
number of other ethical, policy, and 
social concerns, 16,  17 one of the most 
controversial of which is detection of 
infant “premutation” carriers (55–
200 CGG repeats). Recent reports 
recommend that if carrier status is 
detected in children, results should 
be returned to parents. 18, 19 But FXS 
presents an unusual ethical challenge 
because parents, one of whom will be 
implicated as a fragile X (FX) carrier, 
themselves may have a variety of 
health, cognitive, and emotional 
problems. Female carriers are at risk 
for FX-associated primary ovarian 
insufficiency (FXPOI) 20 and both 
sexes are at risk for FX-associated 
tremor ataxia syndrome (FXTAS). 21 
Some carriers are also at risk for 
learning problems and brain function 
abnormalities, autism spectrum 
features, attention and visual 
perceptual deficits, and depression 
or anxiety disorders. 22 – 26
In 2008, we received funding from 
the National Institutes of Health to 
conduct a prospective, longitudinal 
pilot study to address some of the 
concerns about NBS for FXS. We 
framed the study as the social science 
equivalent of an early phase clinical 
trial, typically designed to determine 
the acceptability of a treatment, 
tolerable doses, feasibility, and 
safety, essential information 
before embarking on a larger efficacy 
trial. Accordingly, our primary 
goal was not to prove benefit from 
screening, but rather to assess 
public acceptance and determine 
whether identification of babies 
resulted in any measurable harm or 
adverse events. In addition, we had 
3 secondary goals: determine the 
prevalence of FMR1 carrier 
gene expansion, study the consent 
process, and describe early 
development and behavior of 
identified children.
The study was a partnership between 
investigators at the University 
of North Carolina at Chapel Hill 
(UNC-CH), the University of 
California Davis (UC-Davis) Medical 
Center, and Rush University Medical 
Center (RUMC). Initially, our sites 
were not linked, because we were 
preparing separate applications to 
a request for applications from the 
Eunice Kennedy Shriver National 
Institute for Child Health and Human 
Development for FX research centers. 
We knew of our respective plans and 
initially discussed collaboration, but 
did not link applications because one 
might be approved and the other not. 
Once both were funded (University of 
California Davis and Rush University 
Medical Center submitted a joint 
application), we applied for and 
received a supplement to harmonize 
recruitment procedures and agree 
on common outcome measures, but 
this took considerable time, and 
thus some aspects of the project 
differed across sites. However, the 
general approach was the same. In 
brief, shortly after giving birth and 
while still in the hospital, parents 
were given information about the 
study and offered voluntary FX 
NBS. Screening was performed on 
consented dried blood spots. Families 
of screen-positive babies were 
contacted and invited to return for a 
diagnostic confirmation and genetic 
counseling. Families were then 
invited to participate in a longitudinal 
study assessing maternal outcomes 
and the development of identified 
infants.
Both teams used a screening test 
that detects individuals with FXS 
and premutation carriers. 27 We 
decided to disclose carrier results 
for 5 reasons: (1) we wanted to 
know how many parents would 
agree to a screening test that 
detected carriers; (2) it provided 
an unprecedented opportunity to 
assess whether any symptoms might 
be apparent in early childhood; (3) 
knowing infant carrier status meant 
that 1 parent was a carrier and other 
family members may have either 
a premutation or full mutation, 
information that could be important 
to some families for reproductive 
planning and for potential additional 
health issues for carriers; (4) it 
provided the opportunity to study 
prevalence in a relatively unbiased 
population; and (5) ultimately, 
we had no ethical justification for 
withholding this information from 
parents.
This article summarizes our major 
findings, presented as “lessons 
learned.” Our hope is to provide 
information that might be useful 
for investigators conducting similar 
studies on FX or other conditions. We 
conclude by discussing the challenges 
inherent in providing evidence 
needed to evaluate the benefits of 
NBS for rare disorders.
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LESSON 1: IN-HOSPITAL CONSENT IS 
POSSIBLE BUT CHALLENGING
The recruitment and consent process 
is detailed in earlier publications. 27,  28 
In brief, a recruiter approached 
families shortly after birth and 
asked if they were interested in 
learning about a research study. If 
they agreed, the recruiter provided 
a copy of the consent form and a 
brochure. Some parents were ready 
to decide immediately, but most had 
a few hours to consider, after which, 
the recruiter returned to ascertain 
willingness to participate.
The process worked, but the magnitude 
of burden and the inherent challenges 
in consenting during this time were 
substantial. By any standard, asking 
mothers to consider a research study 
within a few hours of birth is far from 
ideal. Prenatal consent would have 
been preferable, but coordination 
with all prenatal providers associated 
with each hospital was not feasible or 
affordable. We hired our own recruiters 
because we could not expect hospital 
staff to convey the complex implications 
of FXS and previous research had 
demonstrated lack of follow-through 
when relying on hospital staff. 29 
Bilingual recruiters were available to 
talk with the substantial proportion 
of Spanish-speaking families, and all 
written materials were available in 
both English and Spanish. Limited 
funding meant that we were not always 
able to recruit at night or on weekends 
or holidays.
Most NBS today is conducted without 
consent on the assumption that 
a public health mandate and the 
interest of the infant are sufficiently 
compelling to warrant screening 
without consent. Although generally 
well-accepted, mandatory screening 
has been the subject of considerable 
debate, 30 and some have argued that 
the changing nature of screening 
may suggest a reconsideration of 
voluntary consent. 31 However, the 
broader challenges of informed 
consent 32 and our data suggest 
that consent for NBS conducted in 
the hospital will be an enormous 
informational and logistical burden.
LESSON 2: ALMOST TWO-THIRDS OF 
FAMILIES AGREED TO HAVE THEIR 
CHILD SCREENED
In 2011 we reported initial (15-
month) findings about parents’ 
decisions to participate at the North 
Carolina site. 28 Recruiters approached 
2137 mothers, of whom 95.7% were 
willing to hear about the study and, of 
those, 63% of couples agreed to have 
their child screened. By the time the 
project ended in 2014, across all 3 
sites, screening was offered to >28 000 
families, with an acceptance rate of 
62% and >17 000 infants screened.
Our earlier surveys of parents of 
children with FXS found a higher 
acceptance of NBS for FXS and for 
return of results of carrier status 
(>80%) compared with the pilot 
study. 5,  6 Parents of an affected child 
are understandably more interested 
in earlier identification; most would 
have preferred to avoid a lengthy 
diagnostic odyssey, but the general 
public has not had this experience. 
We conclude that the majority of the 
population would accept NBS for FXS 
and for carrier status. But, clearly, a 
substantial portion do not want NBS 
or would not be able to decide in the 
hospital. This finding has implications 
for other conditions for which there 
are no proven treatments that must 
be provided during early childhood. 
Knowing that more than one-third 
of families question the desirability 
of FX NBS significantly weakens any 
justification for mandatory screening 
for such conditions until stronger 
evidence of benefit is demonstrated.
LESSON 3: THE REQUIREMENT 
TO OBTAIN CONSENT FROM BOTH 
MOTHERS AND FATHERS PROVIDED 
AN ADDED CHALLENGE BUT ALSO AN 
OPPORTUNITY TO DEVELOP GUIDANCE 
FOR DECISION-MAKING
We submitted separate institutional 
review board (IRB) applications for 
each site. The IRBs differed in their 
assessment of risks and benefits, with 
implications for recruitment. The 
RUMC IRB determined that the study 
met the standard for greater than 
minimal risk, but with the potential 
for direct benefit, a federal code of 
§46.405/§50.52. 33 The UNC-CH and 
UC-Davis IRBs determined that the 
study was greater than minimal 
risk, but with no potential for direct 
benefit to the infant and coded 
the study §46.405/§50.53. These 
decisions meant that at those sites, 
we were required to get permission 
from both parents, if “reasonably 
available, ” whereas only the mothers’ 
permission was needed at RUMC.
A report based on our North 
Carolina sample found that 68% 
of mothers who heard about the 
study agreed to participate, but the 
overall acceptance rate dropped 
to 64% when fathers were taken 
into account. 34 In nearly 20% of 
cases, the father was not present in 
the hospital. Of those, ∼60% were 
considered “not reasonably available, ” 
and we were able to use the mother’s 
consent. In the remaining cases, the 
father was considered “reasonably 
available” and was sent a consent 
form. Of those, only 30% returned a 
signed form.
To the best of our knowledge, we are 
the first to report a detailed analysis 
of father involvement in the consent 
process for research purposes 
involving couples. Throughout the 
process, we consulted with IRB 
officials and legal counsel to clarify 
definitions of “reasonably available” 
and outline the steps necessary 
before making a final determination 
of whether the father’s consent was 
needed. We created an algorithm to 
help other investigators conducting 
research in which permission from 
both parents is required. 34
Although we do not fully agree with 
the IRBs that determined there was 
no potential for direct benefit to 
the child, we do not have empirical 
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data to support that argument. 
We do agree that, ideally, both 
parents should be involved in the 
consent process. FX NBS has the 
potential to implicate either the 
mother or the father as a carrier, 
and the identification of a screen-
positive infant inevitably has 
broader implications for extended 
family members. Case studies 
from one of our sites, for example, 
showed that identifying 1 child can 
lead to the identification of many 
extended family members as either 
premutation carriers or individuals 
with FXS. 35 Such extended family 
ramifications suggest the importance 
of both parents consenting, but the 
dual consent requirement raises 
other ethical issues; for example 
when the mother clearly wants 
screening, but the father does not. 
Regardless, we have shown that 
obtaining consent from both 
parents requires substantial time 
and resources and presents 
challenging decisions regarding 
the “reasonably available” 
standard.
LESSON 4: REASONS FOR ACCEPTING 
OR DECLINING VARIED ACROSS 
FAMILIES AND PARTICIPATION WAS 
ASSOCIATED WITH ETHNICITY
Why did parents accept or decline 
screening? In our initial article from 
the North Carolina site, we reported 
that the most common reasons for 
accepting focused on the desire to 
know important information about 
their child, belief in the importance 
of supporting research, and the 
perception of minimal risk. 27 Those 
who declined did not want to 
worry about their child, had issues 
with testing very young children, 
preferred to wait until symptoms 
appear, or reported that the timing 
of consent made it difficult for them 
to decide. African American families 
were significantly less likely to 
accept screening. This acceptance 
rate and the lower participation by 
African American families remained 
relatively constant across time and 
across sites. 28
We are currently completing a more 
detailed analysis of reasons for 
accepting or declining as a function 
of ethnicity. The RUMC and UC-Davis 
sites are also completing a more 
detailed analysis of reasons for 
consenting or declining.
Our results reflect the majority 
of parents’ basic desire to know 
anything that might impact the 
baby as soon as possible, but there 
is a significant minority who do not 
need or want to know unless the 
baby begins to show symptoms. In 
the absence of a defined treatment 
that can change the course of 
development in FXS, both of these 
viewpoints are reasonable, and thus, 
ways of approaching screening that 
can accommodate both perspectives 
are needed.
LESSON 5: HIGH-QUALITY CONSENT 
MATERIALS CAN AID INFORMED 
DECISION-MAKING ABOUT STUDY 
PARTICIPATION, BUT EVEN THE 
BEST MATERIALS HAVE LIMITED 
EFFECTIVENESS IN THE CONTEXT OF 
IN-HOSPITAL CONSENT
About 2 years into the project, we 
decided to change the recruitment 
brochure, for several reasons. First, 
fewer than half of parents reported 
looking at the old brochure, so we 
wanted to create a new brochure that 
was more visually appealing. Second, 
because almost all identified cases 
were carriers, we wanted to convey 
more clearly the meaning of carrier 
status and the likelihood of carrier 
identification. Third, recognizing 
the differences in acceptance rate 
by ethnicity, we wanted to convey 
pictorially the fact that FX affects all 
races/ethnicities. Finally, we wanted 
a tool to help the recruiters support 
families in making truly informed 
decisions about study participation.
To guide the development of the new 
brochure, we drew on the principles 
of informed decision-making (IDM), 
a proven approach to develop tools 
that help people participate in health 
decisions in ways they prefer. 36 
IDM is typically used when there is 
>1 medically reasonable option to 
diagnose or treat a health problem. 
IDM tools provide information and 
help people clarify their values when 
making a decision for which there is 
not one right answer. 37
We used an iterative process with 
multiple review points to develop 
a brochure in accordance with 
IDM standards. The brochure was 
colorful and informative, providing 
clear descriptions of the study, the 
effects of FXS, and the meaning 
of carrier status, and it concluded 
with a balanced set of reasons why 
parents might or might not want to 
participate. The brochure received 
high ratings from an independent 
review group. In a simulation study, 
we found that it took women about 
6.5 minutes to read the brochure, 
and they scored an average of 91.1% 
correct on a follow-up knowledge 
test. 38 Minority and white mothers 
did not differ in their perceptions of 
quality of the brochure or trust of the 
information. We still found that more 
white (64%) and Hispanic (75%) 
mothers compared with African 
American mothers (57%) reported 
that they would probably agree to 
screening, but this difference was not 
statistically significant.
The brochure was translated 
into Spanish, slight site-specific 
modifications in the text were 
made, and all sites began using it. 
The UNC-CH site used a pre–post-
intervention design to determine 
whether the new brochure enabled 
informed decisions. 39 We found that 
families were more likely to look at 
the new decision aid, but only 14% 
of the mothers (as compared with 
11% with the original brochure) 
reported having read the entire 
brochure.
With few exceptions, 40 this is one 
of the first efforts to use IDM in a 
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research context, as opposed to 
decision-making for the purpose of 
health care. We are confident that 
the new brochure was a significant 
improvement over the original and, 
if read, would be a great help in 
supporting informed decisions. We 
had hoped it would also reduce the 
time needed by recruiters, but that 
was not possible given that so few 
women read it. Our findings 
reiterate the importance of the 
context in which consent is 
requested, and suggest that better 
materials alone, at least in the format 
we developed, will not be sufficient 
to make the consent process more 
efficient.
LESSON 6: UNLIKE MOST CURRENT 
NBS TESTS, THE SCREENING METHOD 
WE USED WAS VIRTUALLY DIAGNOSTIC
The screening methodology we used 
is a polymerase chain reaction (PCR)-
based approach  28,  41 that allows 
the detection of FMR1 expanded 
alleles and provides precise data 
on the allele CGG repeat number, 
from the normal through the full 
mutation range, in both sexes. We 
found consistent agreement between 
screening data performed from the 
blood spot cards and PCR-based 
confirmatory testing performed on 
whole blood for all the newborns 
that tested positive (usually within 
2–5 CGG repeat lengths). The 
classification of infants (normal, 
premutation, full mutation) based 
on screening data was the same 
as the final classification based 
on confirmatory testing, with the 
exception of 3 infants, resulting from 
a calibration error in the screening 
laboratory (not an error in the 
laboratory test itself).
NBS today often results in a large 
number of false positives, on the 
assumption that it is better to identify 
a child who does not have a disease 
than to miss an affected infant. We 
show that as NBS moves toward 
genetic screening (as opposed to, 
for example, testing analytes that 
could be affected by factors such as 
gestational age and birth weight 42), 
the result could be greater precision 
in screening data, potentially 
reducing costs of unnecessary 
repeat or confirmatory tests and the 
associated parent anxiety. Of course, 
the counterargument is that genetic 
screening has the potential to identify 
individuals with a genetic mutation, 
but for whom there are no clinical 
symptoms, creating a different kind 
of anxiety in parents who do not 
know whether their children will 
have a problem or not, 43 a problem 
that will only be more complicated if 
whole exome or genome sequencing 
becomes part of NBS. 44 We know 
that in the case of FX carriers, only 
a subset of individuals experience 
outcomes such as FXTAS or FXPOI or 
other health problems in adulthood, 
and there is currently no biomarker 
to differentiate who is or is not 
at additional risk for poor health, 
emotional, or learning outcomes.
LESSON 7: POPULATION SCREENING 
PROVIDED A MORE ROBUST ESTIMATE 
OF PREVALENCE RATES FOR FMR1 
PREMUTATION CARRIERS
We found a premutation prevalence 
rate of 1 per 209 females and 1 
per 430 males. 27 These results are 
in general agreement with other 
recent population screening studies, 
suggesting that the prevalence 
of premutation alleles is higher 
than previous estimates. 45 – 47 
Full mutation alleles may be less 
common than previously reported; 
indeed, we identified only 1 male 
carrying the full mutation. 
However, a much larger sample 
size would be needed to obtain 
accurate estimates of full mutation 
prevalence.48
A key requirement for NBS is 
understanding the true prevalence of 
a condition, to estimate the individual 
and public health burden of the 
disease, and to plan appropriately 
for the scope of needed follow-up 
and support services. The only way 
to get accurate prevalence data 
is through population screening. 
Because only two-thirds of invited 
families chose to have their child 
screened, we cannot claim that 
this is a completely unbiased, 
representative sample, but the size 
and distribution of our sample give 
us more confidence in these data 
and add to the growing literature 
suggesting that premutation carriers 
are more common in the general 
population than earlier estimates. 
The implications of this finding are 
twofold. First, from a public health 
perspective, we now know that many 
more individuals in the general 
population are at risk for having 
a child with FXS or experiencing 
conditions, such as FXTAS or FXPOI, 
that are commonly associated with 
carrier status, creating a need for 
more awareness among clinicians 
and researchers to understand 
mechanisms and treatments. Second, 
from the perspective of NBS, the 
identification of premutation carriers 
poses a clear burden for which NBS 
counseling and follow-up programs 
are currently unprepared. For 
example, in North Carolina, which 
has a birth rate of ∼120 000 infants 
per year, we estimate that NBS would 
identify 15 boys and 15 girls with 
FXS per year (assuming a 1:4000 
FXS prevalence rate). However, 
based on our prevalence estimates, 
a PCR-based test would also identify 
∼140 boy and 287 girl carriers. 
NBS follow-up programs, primary 
care physicians, geneticists, and 
genetic counselors would face the 
challenge of providing information 
and counseling for a large number 
of families, genetic testing of other 
family members (both nuclear and 
extended), and surveillance and 
support throughout the childhood 
and adolescent years to monitor 
potential problems and help 
parents decide when to inform 
children of their carrier status and 
implications.
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LESSON 8: MOST SCREEN-POSITIVE 
BABIES WILL BE CARRIERS WITH LOW 
CGG REPEAT LENGTHS
Of the premutation carrier infants 
identified, we found that ∼70% 
carried an FMR1 allele with <70 CGG 
repeats, confirming preliminary 
results from other studies. 28,  45,  49 
This skewed distribution could have 
substantial implications for genetic 
counseling of carriers harboring 
smaller alleles, who may therefore 
have a lower risk of developing 
FXTAS and other psychiatric, 
cognitive, and motor problems. 50 – 53 
Analysis of AGG interruptions 
within the FMR1 gene is needed 
to determine allele stability and 
more accurately estimate the risk 
of expansion to a full mutation with 
transmission, which is particularly 
important in women with a 
premutation allele in the 55 to 70 
range, adding to the complexity 
of follow-up genetic counseling in 
screen-positive cases. 54,  55 Infants 
with low CGG repeat lengths may 
have little risk themselves of having 
a child with the FMR1 full mutation, 
and their parents would likely have 
a CGG repeat length equal to or less 
than the infant’s and also may have 
a relatively small chance of having 
a child with the full mutation, thus 
lessening the potential benefit 
from knowledge of reproductive 
risk and potentially raising greater 
uncertainty about multigenerational 
implications. However, premutation 
carriers may be at risk of presenting 
with neurodevelopmental problems 
even in the lower premutation 
range, 21 and some data suggest 
a curvilinear pattern in which 
individuals with mid-range CGG 
repeats are at greater risk for health 
or mental health consequences 
than individuals with very short or 
very long repeats in the CGG repeat 
continuum. 24,  56 –59 Unfortunately, 
we have imperfect knowledge about 
phenotype-genotype correlations 
within the carrier range, data that 
can only be gathered through 
systematic longitudinal research 
based on population screening 
of large samples. These data and 
accompanying ethical discussions 
and treatment studies ultimately 
are needed to guide decisions 
regarding CGG cut-offs to guide the 
return of results and the certainty of 
information for families.
LESSON 9: FOLLOW-UP COUNSELING 
IS COMPLICATED, AND FAMILY 
PARTICIPATION IN DIAGNOSTIC 
CONFIRMATION AND LONGITUDINAL 
FOLLOW-UP WAS NOT UNIVERSAL
A physician on the research team 
attempted to contact all families 
whose baby received a positive 
screen to offer genetic counseling 
and confirmatory testing. Families 
were then invited to a genetic 
counseling session where the results 
were reviewed, a family history was 
obtained, confirmatory testing was 
conducted with the infant, and other 
family members were offered testing 
if they wanted it. The initial phone 
call provided a reminder and context 
for the screening, which families 
did not always remember given the 
timing of the consent during the 
postpartum time frame, as well as 
the 6- to 8-week lag between the 
birth of the child and the results. 
Of the 46 babies who screened 
positive for an FMR1 mutation (45 
premutation, 1 full mutation), 30 
received confirmatory testing and 
genetic counseling. Sixteen families 
did not receive follow-up counseling 
or confirmatory testing due to the 
following reasons: (1) they were 
unable to be reached by phone 
or mail (n = 8); (2) they declined 
genetic counseling (n = 3) or 
repeat testing (n = 3); or (3) they 
did not show up for the appointment 
(n = 2).
The complex nature of inheritance 
and transmission of expansions 
in the FMR1 gene, the age-related 
penetrance and variable expressivity 
of pre- and full mutations, and 
comorbidities, such as anxiety in 
premutation carriers, contributed to 
the challenges of providing adequate 
genetic counseling and psychosocial 
support for screen-positive infants 
and their families. Multiple phone 
calls and clinic visits with the genetic 
counselor and geneticist were 
sometimes required.
Three of the screen-positive babies 
that were above the cutoff of 55 CGG 
repeats had confirmatory testing 
that showed 2 of them with a gray 
zone expansion (CGG = 50, 51) and 
1 with an allele in the normal range 
(CGG = 30). These false positives 
were determined to be due to a 
calibration error at the laboratory, 
which was quickly corrected. 
One additional boy infant’s 
results indicated the presence of 
2 FMR1 alleles, 1 of which had a 
premutation. Chromosome analysis 
confirmed the suspicion of 47, 
XXY (Klinefelter syndrome), and 
the family was counseled about 
both findings. Although rare, these 
false positive and secondary or 
unanticipated findings complicate 
the genetic counseling process.
Additional complicating matters 
for families is the pressure to 
inform other family members of 
their genetic risk. Extended family 
members may not hear about their 
potential to be a carrier until they 
interact with the primary family 
who received the information 
initially. Some extended family 
members may be grateful for the 
genetic counseling information even 
when the primary family may not be 
appreciative, whereas others would 
have preferred not to know.
All families who received 
confirmatory testing and genetic 
counseling were invited to 
participate in a longitudinal 
follow-up study. The longitudinal 
assessments consisted of quantitative 
measures and semistructured 
interviews to determine whether 
families experienced adverse mental 
health outcomes after a diagnosis 
and the extent to which they believed 
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they were adequately informed about 
possible results from screening, 
were satisfied with their decision 
to participate, and whether and 
how their views about screening 
changed over time. In addition, 
measures of child social, cognitive, 
adaptive, emotional, and behavioral 
development were conducted. A 
sample of families whose children did 
not screen positive for FX, matched 
on ethnicity, language, education, and 
income with the sample of screen-
positive families, was recruited as a 
comparison group. Assessments of 
the baby and family were conducted 
at 6-month intervals. Most of the 
families with a positive confirmatory 
test agreed to participate in at 
least 1 longitudinal assessment 
(26/28; 93%). Six families received 
1 evaluation, but did not respond 
to requests to schedule a second 
assessment. We found that having 
a developmental specialist present 
during the genetic counseling session 
to provide an initial assessment of 
the infant’s development and discuss 
milestones tended to lead to greater 
participation in the longitudinal 
assessments.
The families who stayed in follow-up 
seemed to become more positive 
about their decision to participate 
as time went on because they felt 
they had an opportunity to ask 
questions and go over their child’s 
development and behavior with 
the research team, including the 
psychologist and physician. They 
felt the visits were valuable based 
on the suggestions and reassurance 
they received during the study visits. 
If families received a diagnosis 
without options for this follow-up to 
occur, they might not be as positive 
about the information. This finding 
raises questions about the amount 
of resources needed to support 
families with children found to 
have a premutation for an extended 
period.
LESSON 10: MOTHERS OF IDENTIFIED 
BABIES DID NOT APPEAR TO HAVE 
WORSE MENTAL HEALTH OUTCOMES 
THAN MOTHERS OF SCREEN-NEGATIVE 
INFANTS
Of the many questions and 
concerns about FX NBS, one of 
the most persistent has been 
whether identifying premutation 
carriers would result in negative 
consequences for parents, especially 
for mothers who might experience 
increased postpartum depression, 
anxiety, or stress. 16 We tested 
this assumption by conducting 
longitudinal assessments of these 
variables in mothers of identified 
children and compared their data 
with a matched sample of screen-
negative mothers. We found no 
significant group differences on 
measures of maternal anxiety, 
postpartum depression, parenting 
stress, or family quality of life.
Although these findings cannot 
necessarily be generalized to other 
families or situations, they provide 
important evidence suggesting that 
the anticipated harms of FX NBS 
may not be as likely as some have 
speculated. In part, this may be due 
to the thorough consent process, 
because we tried to make clear to 
parents the implications of deciding 
to participate in the study, and it 
is possible that the families more 
likely to have an adverse reaction 
may have been those who opted out 
of the study initially or who did not 
participate in the longitudinal study. 
Nonetheless, it is important to know 
that it is possible to offer screening in 
a way that minimizes the likelihood 
of adverse reactions.
DISCUSSION
Despite the scope and enormity of 
effort required to implement this 
study, several limitations must be 
acknowledged. First, although we 
offered screening to thousands of 
families and screened thousands 
of babies, the sample size remains 
small for answering questions, such 
as the prevalence of full mutation 
infants, ethnic variation in CGG 
repeat expansion in the full mutation 
range, family adaptation, and infant 
developmental status. Second, the 
study was limited to 3 university-
based hospitals, and although the 
patient populations in these hospitals 
were quite diverse, the findings may 
not be generalizable to the United 
States more broadly. Third, there 
may be family characteristics that 
we did not assess that could have 
contributed to parents’ willingness 
to have their baby screened, and the 
parents who agreed to participate 
in the longitudinal study may be 
different from those who did not 
(although we found no differences in 
maternal age, marital status, race/
ethnicity, maternal education, and 
CGG repeat length of the identified 
child). 60 Finally, the study was not 
designed to prove benefit for children 
and, as such, does not answer the 
ultimate question of whether FX NBS 
is good public policy.
Nonetheless, the study provides 
answers to a number of heretofore 
unanswered questions, and 
hopefully advances the field 
toward a better understanding of 
the nature and consequences of 
offering FX NBS. What research or 
other discoveries are now needed 
to determine whether and how 
NBS should be offered for FXS? 
In a companion article in this 
supplement, “Implications of the 
FMR1 Premutation for Children, 
Adolescents, Adults, and Their 
Families, ” Wheeler et al identify 
issues and barriers related to NBS for 
FXS and present the strengths and 
challenges of potential approaches 
to addressing them. As with all 
rare diseases, each question would 
require a considerable investment 
to answer. Because most candidate 
conditions are rare, the challenges 
that must be overcome to provide 
the necessary evidence base are 
enormous. Classic criteria for NBS 
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include a thorough understanding 
of first symptoms, early phenotypic 
expression, the life course of the 
disease, genotype-phenotype 
correlations, and the efficacy of 
presymptomatic treatments. But 
researchers seeking to provide this 
information are caught in a classic 
“catch 22” situation: screening 
cannot be justified because of 
insufficient research, but the research 
that must be conducted is impossible 
without some sort of population 
screening. Unfortunately, there is 
no clear mechanism for prioritizing 
these issues, but it seems logical that 
advances would be most efficacious 
if a deliberative strategy could be 
identified and teams of investigators 
could work together to solve them. 
Ultimately, a standing resource for 
evaluating candidate conditions for 
NBS could expedite needed research 
to answer pressing policy issues 
and provide the data needed before 
conditions can be recommended for 
inclusion in state NBS programs. 61
In the meantime, families continue 
to experience problems and 
frustrations in the delayed diagnosis 
of children with FXS, and a number 
of practical strategies have been 
suggested to advance earlier 
identification. 62 Certainly, better 
training for physicians and other 
health professionals in conducting 
regular developmental screenings 
and responding to parents’ 
concerns would help, but FXS is so 
nonspecific in its presentation that 
any symptom-based approach to 
earlier identification would probably 
have a limited impact on the age of 
diagnosis. Population screening in 
some form will likely be the only 
realistic way to identify early all 
children with FX mutations for 
their benefit and the benefit of their 
families.
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